Professor Regina E. Herzlinger Joins Noven's Board of Directors

-- Noven Pharmaceuticals, Inc. (Nasdaq:NOVN) has announced the appointment of Regina E. Herzlinger to its board of directors.

Professor Herzlinger holds the Nancy R. McPherson Professor of Business Administration Chair at the Harvard Business School. During her thirty-year career at the Harvard Business School, she has specialized in issues relating to health care, management control systems and nonprofit organizations. She has authored a broad range of books and articles in these and other areas, and her research has been profiled in industry journals and national business publications, including Business Week, The Economist, Forbes and Fortune. Professor Herzlinger was the first woman to be tenured at the Harvard Business School.

Professor Herzlinger has been recognized for excellence in research three times by the American College of Healthcare Executives. She has twice won the Thompson Book of the Year Award, and Managed Healthcare named her as one of health care's top ten thinkers in 1999. She was named the first CIMA Visiting Professor at the University of Edinburgh in recognition of her work in nonprofit accounting and control.

Professor Herzlinger is a board member of several public companies, including Schering-Plough Corporation and Cardinal Health, Inc. She received her Doctorate from the Harvard Business School and her Bachelor's degree from the Massachusetts Institute of Technology.

"Professor Herzlinger brings a wealth of business and health care experience to Noven's board of directors," said Robert C. Strauss, Noven's President, Chief Executive Officer and Co-Chairman. "Her insight and direction will help Noven continue to improve its business."

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leader in the development of transdermal and transmucosal drug delivery technologies and products. Together with Novartis Pharmaceuticals, Noven owns a women's health products company called Novogyne Pharmaceuticals, which is the only company in the U.S. offering transdermal therapies for both the estrogen-only and combination hormone therapy markets. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot™, licensed to Novogyne, and Estradot™, licensed to Novartis) and combination estrogen/progestin transdermal delivery systems (including Combipatch™, licensed to Novogyne, and Estalis® licensed to Novartis). With a range of additional products in development, Noven is committed to becoming the world's premier developer, manufacturer and marketer of transdermal and transmucosal drug delivery systems.

Investor & Media Contact:
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.